Patients with obesity and metabolic syndrome : Weight reduction achieved through GLP-1 therapy often correlates with improvements in the characteristic dyslipidaemia of metabolic syndrome (elevated triglycerides, low HDL cholesterol, and small dense LDL particles)
Half of the insulin never gets out of the liver, so half of its action is happening in the liver, and the question is, what's it doing
According to incomplete statistics, sales of Novo Nordisk's semaglutide have been soaring year after year, with 2023 sales surpassing $21.2 billion, making it the first GLP-1 drug to join the "billion-dollar club." Its market position is quickly catching up with Merck's Keytruda, and it has the potential to become the next "blockbuster" drug
GLP-1 agonists mimic this hormone, improving blood sugar levels, slowing the movement of food from the stomach into the small intestine, and helping you feel satiated
Also, new studies showing effectiveness are prompting more doctors to prescribe these drugs